Literature DB >> 10753836

Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera.

S Temerinac1, S Klippel, E Strunck, S Röder, M Lübbert, W Lange, M Azemar, G Meinhardt, H E Schaefer, H L Pahl.   

Abstract

Polycythemia vera (PV) is a clonal stem cell disorder characterized by hyperproliferation of the erythroid, myeloid, and megakaryocytic lineages. Although it has been shown that progenitor cells of patients with PV are hypersensitive to several growth factors, the molecular pathogenesis of this disease remains unknown. To investigate the molecular defects underlying PV, we used subtractive hybridization to isolate complementary DNAs (cDNAs) differentially expressed in patients with PV versus normal controls. We isolated a novel gene, subsequently named PRV-1, which is highly expressed in granulocytes from patients with PV (n = 19), but not detectable in normal control granulocytes (n = 21). Moreover, PRV-1 is not expressed in mononuclear cells from patients with chronic myelogenous leukemia (n = 4) or acute myelogenous leukemia (n = 5) or in granulocytes from patients with essential thrombocythemia (n = 4) or secondary erythrocytosis (n = 4). Northern blot analysis showed that PRV-1 is highly expressed in normal human bone marrow and to a much lesser degree in fetal liver. It is not expressed in a variety of other tissues tested. Although PRV-1 is not expressed in resting granulocytes from normal controls, stimulation of these cells with granulocyte colony-stimulating factor induces PRV-1 expression. The PRV-1 cDNA encodes an open reading frame of 437 amino acids, which contains a signal peptide at the N-terminus and a hydrophobic segment at the C-terminus. In addition, PRV-1 contains 2 cysteine-rich domains homologous to those found in the uPAR/Ly6/CD59/snake toxin-receptor superfamily. We therefore propose that PRV-1 represents a novel hematopoietic receptor. (Blood. 2000;95:2569-2576)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10753836

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Basic sciences of the myeloproliferative diseases: pathogenic mechanisms of ET and PV.

Authors:  Rosemary E Gale
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 2.  Primary thrombocytosis in children.

Authors:  Nicole Kucine; Katherine M Chastain; Michelle B Mahler; James B Bussel
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

3.  AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Authors:  Wei Wang; Sven Schwemmers; Elizabeth O Hexner; Heike L Pahl
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

4.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

Review 5.  Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions.

Authors:  David F Stroncek; Emmanuel Fadeyi; Sharon Adams
Journal:  Transfus Med Rev       Date:  2007-10

Review 6.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

7.  CD177 modulates human neutrophil migration through activation-mediated integrin and chemoreceptor regulation.

Authors:  Ming Bai; Ricardo Grieshaber-Bouyer; Junxia Wang; Angela B Schmider; Zachary S Wilson; Liling Zeng; Olha Halyabar; Matthew D Godin; Hung N Nguyen; Anaïs Levescot; Pierre Cunin; Craig T Lefort; Roy J Soberman; Peter A Nigrovic
Journal:  Blood       Date:  2017-08-14       Impact factor: 22.113

8.  Quantification of clonal hematopoiesis in polycythemia vera.

Authors:  Udo Siebolts; Murat Ates; Rüdiger Spitz; Jürgen Thiele; Claudia Wickenhauser
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

9.  The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.

Authors:  Lisa Pieri; Costanza Bogani; Paola Guglielmelli; Maria Zingariello; Rosa Alba Rana; Niccolò Bartalucci; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Authors:  Donna M Williams; Ann H Kim; Ophelia Rogers; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2007-10-17       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.